Charles River Laboratories Intl. Inc vs Global Payments Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Global Payments Inc trades at $82.2 (market cap $21.46B). The key difference: Global Payments Inc is the larger of the two by market cap, and Global Payments Inc pays a 1.23% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Global Payments Inc for 50 Days on average.
| CRL | GPN | |
|---|---|---|
Market Cap | $14.23B | $21.46B |
Volume | 1,176,885 | 1,482,600 |
Sector | Health | Financials |
52-Week High | $310.77 | $94.83 |
52-Week Low | $149.93 | $62.47 |
Typical Hold Time | 33 Days | 50 Days |
Enterprise Value | $17.06B | $39.60B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
Global Payments (GPN) trades at $82.77, up 2.08% with a neutral technical signal despite bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net income margin and ROE. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains strongly bullish with a $102.75 price target.
GPN presents a mixed outlook with strong analyst support and strategic initiatives offset by profitability concerns and rising debt levels. The stock offers 24% upside to consensus targets but faces execution risks in integrating acquisitions and maintaining margin expansion amid competitive pressures in the payments technology sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →